www.seagen.com<\/a> and follow @SeagenGlobal on Twitter.<\/p>\nForward-Looking Statements<\/b><\/p>\n
\nCertain of the statements made in this press release are forward looking, such as those, among others, relating to Pfizer\u2019s proposed acquisition of the Company; the anticipated timing of completion of the proposed acquisition; the Company\u2019s potential to achieve the noted development and regulatory milestones in 2023, in future periods or at all; the Company\u2019s pipeline and technologies; anticipated activities related to the Company\u2019s planned and ongoing clinical trials; the potential for the Company\u2019s clinical trials to support further development, regulatory submissions and potential marketing approvals in the U.S. and in other countries; the potential for the EV-302 clinical trial and the innovaTV 301 clinical trial to serve as confirmatory trials to support the continued approval of PADCEV in its first-line la\/mUC indication in the U.S. or of TIVDAK in its indication in the U.S., respectively; the opportunities for, and the therapeutic and commercial potential of ADCETRIS, PADCEV, TUKYSA, TIVDAK, the Company\u2019s product candidates and the products and product candidates of its licensees and collaborators; plans with respect to regulatory submissions; as well as other statements that are not historical fact. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include without limitation: risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by Seagen stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; disruption from the transaction making it more difficult to maintain business and operational relationships; significant transaction costs; unknown liabilities; the risk of litigation and\/or regulatory actions related to the proposed acquisition or Seagen\u2019s business; risks related to the financing of the transaction; the risks that the Company\u2019s ADCETRIS, PADCEV, TUKYSA and TIVDAK net sales, revenues, expenses, costs, and other financial guidance may not be as expected; risks and uncertainties associated with maintaining or increasing sales of ADCETRIS, PADCEV, TUKYSA and TIVDAK due to competition, adverse events, regulatory action, reimbursement, market adoption by physicians, drug pricing reform, impacts associated with COVID-19 or other factors; the risk that the Company or its collaborators may be delayed or unsuccessful in planned clinical trial initiations, enrollment in and conduct of clinical trials, obtaining data from clinical trials, planned regulatory submissions, and regulatory approvals in the U.S. and in other countries in each case for a variety of reasons including the difficulty and uncertainty of pharmaceutical product development, negative or disappointing clinical trial results, unexpected adverse events or regulatory actions and the inherent uncertainty associated with the regulatory approval process; the possibility that the Company may encounter challenges in commercializing its therapeutic agents, including with respect to reimbursement, compliance, operational or other matters; the possibility of delays or setbacks in obtaining pricing and reimbursement approvals or otherwise commercializing PADCEV and TUKYSA in Europe and other jurisdictions; risks relating to the Company\u2019s collaboration agreements and its ability to achieve progress dependent milestones thereunder; risks related to the COVID-19 pandemic and resulting economic, financial and healthcare system disruptions; risks associated with the ongoing military conflict between Russia and Ukraine, related sanctions imposed against Russia, and related economic, financial and geopolitical disruptions; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; and changes in laws, regulations, rates and policies. More information about the risks and uncertainties faced by the Company is contained under the caption \u201cRisk Factors\u201d included in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2022 and the Company\u2019s subsequent periodic reports filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.<\/p>\n
Additional Information and Where to Find It<\/b><\/p>\n
\nIn connection with the proposed transaction with Pfizer, Seagen will be filing documents with the SEC, and has filed a definitive proxy statement relating to the proposed transaction. The definitive proxy statement has been mailed to Seagen\u2019s stockholders in connection with the proposed transaction. This communication is not a substitute for the proxy statement or any other document that may be filed by Seagen with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE DEFINITIVE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any vote in respect of resolutions to be proposed at Seagen\u2019s stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in Seagen\u2019s proxy statement. Investors and security holders may obtain free copies of these documents and other related documents filed with the SEC at the SEC\u2019s web site at www.sec.gov<\/a>, or at investor.seagen.com<\/a>.<\/p>\nNo Offer or Solicitation<\/b><\/p>\n
\nThis communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.<\/p>\n
Participants in the Solicitation<\/b><\/p>\n
\nSeagen and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be \u201cparticipants\u201d in the solicitation of proxies from stockholders of Seagen in favor of the proposed transaction with Pfizer. Information about Seagen\u2019s directors and executive officers is set forth in Seagen\u2019s proxy statement on Schedule 14A for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 18, 2023. Additional information concerning the interests of Seagen\u2019s participants in the solicitation, which may, in some cases, be different than those of Seagen\u2019s stockholders generally, is set forth in Seagen\u2019s proxy statement relating to the proposed transaction. These documents are available free of charge at the SEC\u2019s web site at www.sec.gov<\/a> and at investor.seagen.com<\/a>.<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230427005306\/en\/828587\/3\/Seagen_Logo_RGB.jpg\"){kind=logo}
<\/td>\n<\/tr>\n